Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Palbociclib - Biotx.ai

Next Previous
X
Search
Drug Profile

Palbociclib - Biotx.ai

Latest Information Update: 23 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotx.ai
  • Class 2 ring heterocyclic compounds; Antineoplastics; Antivirals; Cyclopentanes; Ketones; Monoclonal antibodies; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 07 Nov 2022 Biotx.ai withdraws a phase II trial in COVID-2019 infections in Germany due to due to challenges in patient enrollment(NCT05371275)
  • 25 May 2022 Biotx.ai enters into a commercial partnership before May 2022 with an unknown organization for the development of Palbociclib in COVID-2019 infections (Biotx.ai pipeline, May 2022)
  • 21 Apr 2022 Phase-II clinical trials in COVID-2019 infections in Germany (PO) (NCT05371275)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top